Dallal, Mohammed M., and Shih-Wen Chang. Evans blue dye in the assessment of permeability-surface area product in perfused rat lungs. J. Appl. Physiol. 77(2): 1030-1035, 1994.-Evans blue dye (EBD) has been used extensively as a marker of extravascular protein leakage. We assessed the utility of EBD as an albumin marker in the measurement of permeability-surface area product (PS) in perfused rat lungs and compared the results with PS values obtained using 1251-labeled albumin. In isolated perfused rat lungs, PS was measured by exposure to a perfusate containing EBD (600 pg/ml) and 1251-albumin (1 &i) for exactly 3 min, followed by washout of the intravascular space with fresh perfusate for 6 min. In lungs from normal rats, we found that PS obtained by EBD (PS-EBD) was fivefold higher than PS obtained by 1"51-albumin (I'S-'""I)
Il.92 t 0.32 (SE) vs. 0.42 t 0.03 x 1O-2 '?.minm'.(re' P < 0.051. Similarly, in rats pretreated with ZZ~~UZ&~ c"ntL&idis lipopolysaccharide (2 mg/kg iv), PS-EBD was much higher than RF"1 (2.01 t 0.30 vs. 0.59 t 0.08 X 10 2 cm:'. min? . g-l, P < 0.01). This discrepancy between PS-EBD and I'SJ2"I was not explained by differences in the amount of free marker in perfusate, because the albumin-binding rate for both markers was very high. In addition, prolonged perfusion (40 min) with EBD did not significantly affect pulmonary vasoreact,ivity or water content in rat lungs. A detailed comparison of the kinetics of lung tissue uptake of the two markers showed an initial phase of rapid lung uptake of EBD, followed by parallel uptake of both markers up to 60 min of perfusion. We conclude that although EBD does not cause obvious lung injury, it is not a reliable marker for measurement of vascular permeability in perfused rat lungs. This is most likely due to rapid binding of EBD to lung tissue proteins.
isolat.ed perfused lungs; endotoxin; pulmonary vascular permeability; lung permeability-surface area product INCREASED PULMONARY microvascular permeability is an early marker of lung vascular injury as well as an important determinant in the development of noncardiogenic pulmonary edema. The lung permeability-surface area product (PS) has proven to be a simple and reproducible assessment of pulmonary vascular permeability to macromolecules in isolated perfused lungs (10, 13, 18) . By strictly controlling for factors that might alter vascular surface area, including body weight, lung blood flow, and pulmonary vascular pressures, we have used lung PS measurement to infer changes in pulmonary microvascular permeability in response to various injurious agents such as tumor necrosis factor, protamine sulfate, hyperoxia, and staphylococcal a-toxin (3, 5, 10, 12).
Radiolabeled albumin is a standard marker for measurement of lung PS (6, 14) . Recently, Evans blue dye (EBD), an inexpensive diazo dye that binds tightly to albumin (15, 19) , has been proposed as a useful nonradioactive marker for albumin transfer in cultured endothelial monolayer as well as in isolated perfused lung (l7), although the validity of these conclusions has been questioned (8). EBD, formerly known as T-1824, has been used extensively in the assessment of plasma protein leakage in intact animals (20, 22) . Tissue uptake of EBD was found to correlate well with 1251-labeled albumin content in inflammatory skin lesions in the rabbit and guinea pig in response to a variety of injurious agents (22). Moreover, excellent correlation with '251-albumin was also found in the airways of anesthetized guinea pigs treated with platelet-activating factor (20). However, the presence of a significant correlation does not imply the numerical equivalence of the data, and no previous study, to our knowledge, has used EBD in the formal assessment of pulmonary vascular permeability. Because of the many potential advantages in replacing 1251 with an inexpensive nonradioactive dye as the albumin marker, we assessed in this study the utility of using EBD for PS measurement in isolated perfused rat lungs.
In lungs isolated from control and endotoxin-treated rats and perfused with a blood-free physiological salt solution (PSS) containing albumin, using the single-sample technique originally described by Kern et al. (13) , we compared lung PS values measured with 1251-albumin (PS-'251) with PS measured with EBD (PS-EBD) as the albumin marker. Factors that are known to influence lung PS measurement, such as body size, lung blood flow, pulmonary microvascular pressure (Pmv), and the amount of free marker molecules in perfusate, were controlled for or measured. We also perfused normal rat lungs with EBD-containing perfusate for longer periods of time to assess any potentially deleterious effects of EBD on pulmonary blood flow or vascular reactivity. Finally, we compared the kinetics of EBD and 1251-albumin uptake by rat lung tissue.
METHODS

Isolated Perfused Lungs
Male Sprague-Dawley rats (250-350 g body wt) were purchased from Harlan (Indianapolis, IN) and given free access to food and water. The isolated lung preparation was performed as previously described (16). Briefly, after pentobarbital so-1031 dium anesthesia (70 mg/kg ip), the trachea, pulmonary artery, and left ventricle were cannulated, and the heart and lungs were removed en bloc from the chest cavity and suspended in a humidified chamber at 38°C. The lungs were ventilated using a Harvard small-animal respirator (model 646) with a humid gas mixture consisting of 5% CO,-21% O,-74% N, at 55-60 breaths/min with a tidal volume of 2.5 ml and a positive endexpiratory pressure of 2 cmH,O. The maximal time period between the interruption of pulmonary circulation and establishment of artificial perfusion was 5 min, during which time the lungs were continually ventilated. Lungs were perfused at constant flow (0.03 ml l min-l l g body wt-') with a PSS containing bovine serum albumin (PSS-albumin) at 4 g/100 ml (Sigma Chemical, St. Louis, MO) using a Harvard peristaltic pump (model 1203). The venous outflow pressure was elevated to 5 cmH,O in all experiments to achieve zone 3 condition. The PSS contained (in mM) 119 NaCl, 4.7 KCl, 1.17 MgSO,, 22.6 NaHCO,, 1.18 KHZPO,, 3.2 CaCl,, and 5.5 glucose. The initial 50 ml of perfusate effluent from left ventricle were discarded, leaving 50 ml of cell-and plasma-free recirculating perfusate. Lungs were perfused undisturbed for 20 min to allow equilibration of temperature and pressure before any experimental protocol was conducted. Mean pulmonary arterial inflow pressure (Ppa) was measured continuously with a model P23 AA Statham transducer and recorded on a Soltec chart recorder. Pmv was measured at selected time points with use of a doubleocclusion technique previously described by Dawson et al. (11) . The perfusate temperature was monitored by a temperature probe inserted into the outflow cannula and maintained at 36.5-38OC throughout the experiment.
Preparation of Test Markers
, Sigma Chemical)-was prepared in water at a concentration of 2 g/l00 ml, filtered, and stored at 4OC. To determine the relationship of dye concentration to optical density, a sample of the prepared EBD stock solution was serially diluted in PSS-albumin.
Aliquots (300 ~1) of these dilutions were placed in 96-well plates, and their optical density was measured using a microplate reader (Molecular Devices, Menlo Park, CA) equipped with a 620-nm wavelength filter. Optical density correlated linearly with EBD concentrations ranging from 0 to 50 pg/ml (linear regression coefficient, r = 1). Although we did not perform any experiments on the day on which EBD stock solution was prepared, we found our EBD stock solution to be stable over time. The optical densities of serial dilutions made from the stock solution at the beginning of our study were comparable to those obtained a few weeks later toward the end of the experiment (the latter densities were only 7-12% lower). 12"1-labeled human serum albumin was purchased from ICN Radiochemicals (Irvine, CA). To ensure low free iodine content, we purified '251-albumin every 2 days using the minicolumn technique described by Tuszynski et al. (21) .
Measurement of Lung PS
We used a modification of the single-sample method of Kern et al. (13) to calculate lung PS. After the initial stabilization period, the lungs were perfused in a nonrecirculating fashion with 50 ml of PSS-albumin containing -1 &i of 12?-albumin and 600 pg/ml of EBD. Exactly 3 min later, the perfusate was switched to fresh PSS-albumin, and the lungs were perfused for an additional 6 min, without recirculation, to wash out the radioactivity and EBD from intravascular space. In our pilot experiments, 6 min of washout resulted in >99.5% reduction of the perfusate level of both markers. The lungs were then dissected free, lightly blotted, and weighed (wet lung weight). The radioactivity of lung and perfusate samples was determined in a gamma counter (Micromedic Plus, Irvine, CA). The optical density of perfusate samples was measured spectrophotometritally at 620-nm wavelength, and the concentration of EBD was calculated from a standard curve of EBD in PSS-albumin.
To measure the amount of EBD in the lung, lungs were homogenized in 20 ml of formamide by use of a Tekmar Tissumizer at 50% output for 8 s and incubated at 50°C for 36 h. The homogenate was then centrifuged at 3,900 g for 10 min. The optical density of 1 ml of formamide extract was determined against formamide blank, and its EBD concentration was calculated by interpolation from a standard curve of EBD in formamide. Lung PS was then calculated as follows: PS = marker activity in lung tissue/(marker activity in 1.0 g of perfusate X 3 min X wet lung wt).
In a separate experiment, we determined that our method of extracting EBD from lung tissue did not lead to a systematic error in the measurement of the amount present. We homogenized the lungs in formamide and centrifuged lung tissue as described above. A sample of our EBD stock solution was serially diluted in the lung homogenate supernatant.
Over the concentration range we used in our experiments, we found that the optical densities of EBD diluted in the homogenate supernatant were <lo% higher than those diluted in formamide. This could result in a ~10% overestimation of lung EBD content.
Specific Protocols
Lung PS in control and endotoxin-treated rats. Sixteen rats were divided into two groups (n = 8 each) and given normal saline (control) or Salmonella enteritidis lipopolysaccharide (LPS or endotoxin; Difco, Detroit, MI; 2 mg/kg body wt iv) 2 h before lung isolation. On each experimental day, lungs from control and endotoxin-treated rats were studied using the same preparation of '251-albumin and EBD. PS-'251 and PS-EBD were compared in the same lung.
Binding of lz51 and EBD to albumin. 1251 binding to albumin was assessed daily. A small sample (1.5 ml) of the purified 1251-albumin was placed on the proximal end of a 53 X 5-mm filter paper. The filter paper was allowed to dry before it was vertically suspended in a 20-ml vial, which contained 1.5 ml of 100% ethanol. The solvent was allowed to migrate for 5 min. The filter paper was then cut in half, and the radioactivity of the proximal and distal sections was measured separately. 1251-albumin binding was calculated as follows: radioactivity of proximal half/(radioactivity of proximal half + radioactivity of distal half). EBD binding to albumin was measured in four separate experiments by placing a length of dialysis tubing (Spectra/Par; 12,000-14,000 mol wt exclusion, Spectrum Medical, Los Angeles, CA) containing 4 ml of PSS-albumin in a bath of 50 ml of PSS-albumin containing EBD (600 pg/ml) for 24 h. The concentration of EBD in the dialysate was determined spectrophotometrically.
Effects of EBD on pulmonary vascular reactivity. To determine whether prolonged exposure to EBD has any adverse pulmonary vascular effects, isolated perfused lungs from eight normal rats were challenged with intra-arterial injection of 0.3 pg of angiotensin II (ANG II) followed, 5 min later, by ventilation with 0% o,-5% Co,-95% N, for 5 min (hypoxia). After a second set of ANG II and hypoxic challenges (each separated by 5 min), the perfusate was replaced with fresh PSS-albumin (control group, n = 4) or PSS-albumin containing EBD (600 pg/ml; EBD group, n = 4). Two additional sets (3rd and 4th) of ANG II and hypoxic challenges were then performed at 5-min intervals starting at 5 min after the change to a new perfusate. Mean Ppa responses to ANG II and hypoxia were measured. To account for the day-to-day and interanimal variability, the pressor responses in each lung were expressed as a percentage of the second (baseline) ANG II or hypoxic response. At the end of each experiment, lungs were dissected free, blotted dry, and weighed (wet lung weight). The lungs were then placed in a 50°C oven until constant weight was achieved (dry weight). Wet-to-dry lung weight ratio was then calculated and compared between control and EBD groups.
Time courses of EBD and 125I uptake by the lung. Isolated lungs from 16 rats were divided into four groups (n = 4 each) and perfused with PSS-albumin containing EBD (600 pg/ml) and '251-albumin (1 &i) for 20,40,60, or 120 min. At the end of this perfusion period, the vascular space was washed free of markers with a fresh solution of PSS-albumin in a nonrecirculating manner for 6 min. Lungs were then dissected free, lightly blotted, and weighed. The radioactivity and EBD concentrations in samples of perfusate and lung tissue were determined as described above. Lung tissue extravascular marker uptake was expressed as follows: lung marker activity/( marker activity in 1.0 g of perfusate X wet lung wt). From our earlier PS measurement study, we were able to calculate lung extravascular uptake of markers at 3 min (n = 8).
Statistical Analysis
Data are expressed as means k SE. We used Student's paired t test to compare the Z?S values obtained using 1251-albumin or EBD in the same lung and the Z?S values and other data from control and endotoxin-treated rats (paired for the day of experiment).
Unpaired t test was used to compare lung vascular pressor responses in control and EBD-perfused
lungs. Linear correlation and regression was performed using standard methods on an IBM personal computer. Differences are considered significant when P < 0.05.
RESULTS
PSJz51 and PS-EBD in Control and LPS-Treated Rats
In control rats, PS-EBD was about fivefold higher than PS-1251 from the same lungs (Table 1) . Similarly, in LPS-treated rats, PS-EBD was significantly higher than PS-1251 (3-to 4fold). Moreover the variance was much higher in PS-EBD (17%) than in PS-12'I measurement (7%). When the two measurements from each lung were plotted against each other (Fig. l) , no relationship could be discerned.
Table 1 also shows that PSJ2!jI was more sensitive than PS-EBD in detecting LPS-induced lung injury. PS-1251 was 40% higher in the LPS-injected group than in the control group, whereas PS-EBD was essentially unchanged between the two groups. The body weight, Ppa, and wet lung-to-body weight ratio were similar in control and LPS-treated rats (not shown). However, LPS did cause hemoconcentration (hematocrit 51.3 t 1.8 vs. 43.2 t 0.7%, P < 0.01) and a small but statistically significant increase in baseline Pmv (4.3 t 0.2 vs. 3.6 t 0.1 mmHg, P < 0.05) in perfused lungs.
Binding of Markers to Albumin
The binding rate of 1251 to albumin averaged 99.8 t 0.1% (n = 8). This was not significantly different from the binding rate of EBD to albumin (99.96 t 0%, n = 4).
Effects of EBD on Pulmonary Vascular Reactivity
Rats in control and EBD groups had similar body weights and baseline Ppa and Pmv. The baseline (2nd) pressor responses to ANG II were similar in the two groups (5.0 t 0.2 vs. 5.3 t 1.1 mmHg). Baseline hypoxic response was somewhat higher in the EBD group than in the control group (5.6 t 0.4 vs. 10.3 t 1.9 mmHg, P = 0.06). To account for this difference in baseline pressor response, subsequent pressor responses were expressed as a percentage of the baseline response. The addition of EBD to the perfusate had no effect on baseline Ppa or Pmv, and the subsequent pressor responses to ANG II and hypoxia were not altered (Fig. 2) . At the end of the perfusion period, the lung wet-to-dry weight ratio was not different between control and EBD groups (6.3 t 0.2 vs. 6.5 t 0.2, respectively). Figure 3 shows that the lung uptake of EBD was much more rapid than lung uptake of 1251 during the initial 3 min of perfusion. After this initial period, EBD and 1251 uptakes roughly paralleled each other for the next 60 min. Although both uptake curves appear to plateau after 1 h of perfusion, there was a small increase in lung EBD uptake between 60 and 120 min (not statistically significant). After 2 h of perfusion, the cumulative lung uptake of EBD was 180% of 1251-albumin uptake. When the data from the initial 3 min of perfusion were excluded, there was a significant correlation in the lung uptake of the two markers (Fig. 4) .
Time Courses of 1251 and EBD Uptake by Lung Tissue
DISCUSSION
In this study, we found that in isolated perfused rat lungs the use of EBD as a marker of albumin yielded lung PS values dramatically different from those obtained using the standard 1251-albumin marker. 1) PS-EBD was much higher than PS-1251 measured simultaneously in the same lung, and the measurements were not correlated. 2) PS-EBD, in contrast to PS-1251, did not detect the increase in lung vascular permeability induced by treatment with LPS.
3) The variance in PS-EBD was much higher than the variance in PS-1251. Because the PS-1251 values compared favorably with estimates of lung microvascular permeability with use of other independent techniques (14), we conclude that EBD is not a useful marker for PS measurement in perfused lungs.
We used the single-sample method described by Kern et al. (13, 14) with minor modifications by Czartolomna et al. (10) The control PS-125 I value obtained in this study was similar to that measured previously in our laboratory (10) and compares favorably with the result obtained by Kern and Malik (14) in rabbit lungs. The modest increase in lung PS-1251 after LPS treatment (-40%) was comparable in magnitude to the increase in lung "leak index" observed previously in rats given a similar dose of LPS (7) and to the increase in lung PS after administration of human recombinant tumor necrosis factor (10). That this increase in lung PS reflects changes in permeability and not vascular surface area is suggested by the following. 1) Rats in the two groups had comparable body weights and therefore are likely to have lungs of similar size. 2) All lungs were perfused at equivalent flow rates, and the pulmonary arterial perfusion pressures were comparable in the two groups.
3) The lungs were perfused under zone 3 condition, and therefore the small difference in Pmv could not have caused much additional vascular recruitment.
Furthermore the presence of marked hemoconcentration in these LPS-treated rats and the previously documented elevation in lung eicosanoids and platelet-activating factor levels (Z,4, 7) suggest that this dose of LPS did cause acute lung vascular injury in the rat. Given this finding, the lack of difference FIG. 3. Time courses of lung tissue uptake of EBD vs. 1251-albumin.
After initial 3 min, during which EBD is rapidly taken up by lung, lung tissue uptake of EBD parallels that of '251-albumin. Data are means 2 SE; n = 4 in each group, except 3-min time point, in which n = 8. In an early study, Rawson (19) found that EBD has high affinity and specificity for albumin as long as the dye-to-albumin molar ratio does not exceed 14:l. In our study, the molar ratio of EBD to albumin was close to 1:l. Furthermore, when we dialyzed free EBD from PSS-albumin-EBD solutions, we found that, on the average, 99.96% of the dye was in the bound form. This albumin-binding rate is comparable to that for 1251 (99.8%). Hence, the high PS-EBD values cannot be explained by excess free EBD in lung perfusate.
A second possibility is that our method of extracting EBD from lung tissue led to a systematic overestimation of lung EBD content. As described earlier, we found that optical densities of a sample of our EBD stock solution serially diluted in lung homogenate supernatant were only slightly higher (~10%) than those serially diluted with formamide. This could result in a ~10% overestimation of PS-EBD and lung EBD content. In our lung PS measurements, PS-EBD was 450% higher than PS-1251. Obviously, a systematic overestimation of lung EBD content cannot explain this discrepancy.
Furthermore, although we found 7-12% reduction in the optical densities of our EBD stock solution toward the end of our studies, our PS-EBD values should not be affected, because they are expressed as a ratio of lung to perfusate EBD activity for each experiment.
Additionally, we found no trend in our data to suggest that PS-EBD results obtained using an older batch of the stock solution are significantly different from those obtained using freshly made solution.
A third possible explanation is that EBD may adversely affect the integrity of lung vascular endothelium, leading to increased permeability.
This also seems unlikely, because our PS-1251, measured (9) found that intravascularly injected EBD has an early phase of rapid disappearance from blood that could be explained by dissociation of EBD-albumin complex and fixation of dye to tissue proteins. Although the latter was an in vivo experiment, it is reasonable to expect such dissociation to occur ex vivo in the presence of tissue protein. Our time course study demonstrated an early phase of rapid lung uptake of EBD but not 1251-albumin. This initial phase of rapid EBD uptake is not likely to reflect transvascular albumin leakage. More likely, it reflects fixation of the minute amount of free EBD in perfusate by lung tissue proteins with subsequent dissociation of the EBD-albumin complex and further binding of dissociated dye to lung tissue proteins. After this initial phase, and presumably with tissue proteins saturated with EBD, the lung EBD uptake paralleled lung 1251 uptake with a kinetic pattern compatible with transvascular movement of albumin. As a result, there was a significant correlation between the lung extravascular contents of the two markers when the 3-min time point was excluded. Thus, even though EBD may not serve as a useful marker for transvascular albumin flux, the tissue content of EBD and 1251-albumin may still be correlated, as reported in earlier in vivo studies (20, 22) .
Recently, Patterson et al. (17) claimed that EBD is a "useful marker for quantitating albumin transfer . . . across the intact alveolar-capillary barrier in isolated, perfused rat lung." This conclusion was based on the finding of an excellent correlation between lavage EBD concentration measured spectrophotometrically and lavage protein concentration measured by Lowry assay in lungs perfused for 20 min with EBD under various conditions. Our interpretation of these data is that, in lavage fluid, EBD exists in a form that is tightly bound to albumin. However, there is no evidence that the EBD-albumin complex moves across the alveolar-capillary membrane as an intact molecule. On the basis of our finding in the time course experiment, it is likely that EBD rapidly saturates the lung tissue protein compartment, possibly in the interstitial space, which then gradually exchanges EBD across the alveolar epithelial membrane.
